Meta Information
ID:myostatin-inhibitors
Name:Myostatin Inhibitors
Schema Version:1.5
Alternate Names
- GDF-8 Inhibitors
- Activin Receptor Type IIB Blockers
Active Compound
null
Intervention Type
therapeutic_agent
Delivery
Route:
subcutaneous_injection
Scope:
- systemic
Regulatory Status
- us:investigational_drug
- eu:investigational_drug
- global:research_chemical
Indication
Focus:
- healthspan
- disease_treatment
Description:
Targeting age-related muscle loss (sarcopenia) and specific muscle-wasting diseases by blocking the protein that limits muscle growth.
Typical Protocol
- No established protocol exists for healthspan; all use is investigational.
- Clinical trials for disease have used subcutaneous or intravenous injections every 2-4 weeks.
Expected Cost Mean
Low Cost:
500
High Cost:
2000
Cost Type:
monthly
Description:
Cost for unregulated research chemicals; not covered by insurance.
Summary
Myostatin inhibitors are a class of investigational drugs that block myostatin, a protein that acts as a natural 'brake' on muscle growth. By disabling this brake, these agents can induce significant muscle hypertrophy, making them a powerful theoretical tool against age-related muscle loss (sarcopenia). However, human trials for muscle-wasting diseases have shown mixed results, often increasing muscle mass without a corresponding improvement in functional strength, and have been associated with safety concerns.
Purpose
Potentially reverse age-related muscle loss by promoting significant muscle growth.
Card Summary
A class of investigational drugs that block the body's natural brake on muscle growth, theoretically combating age-related muscle loss but with unproven efficacy and safety for healthspan.
Drug Class
Drugs In Class
- bimagrumab
- landogrozumab
- stamulumab
- domagrozumab
- trevogrumab
- taldefgrobep alfa
- follistatin-gene-therapy
Impact
Score:
3.5
Justification:
Theoretically high impact on sarcopenia, but human data lacks functional benefit and safety evidence.
Evidence
Grade:
C
Score:
3
Justification:
Strong animal data, but human trials for disease show mixed results and lack healthspan focus.
Safety
Score:
8.5
Justification:
Unapproved research chemicals with unknown long-term effects and risks observed in clinical trials.
Flags
- None are approved for human use; typically sourced as unregulated research chemicals.
- Past clinical trials were halted due to adverse events like minor bleeding and vascular issues.
- Long-term effects on the heart, tendons, and systemic metabolism are unknown.
- Observed increases in muscle mass may not translate to proportional gains in functional strength.
Verdict
Highly experimental with major safety concerns; not ready for healthspan applications.
Created
2026-05-06T22:01:11.214259Z
Ai Model
Gemini 2.5 Pro (High)